Literature DB >> 1747049

A prospective randomized trial of perioperative cefazolin treatment in axillary and groin dissection.

D G Coit1, M Peters, M F Brennan.   

Abstract

One hundred thirty-four patients undergoing axillary or inguinal lymph node dissection were randomized to receive perioperative treatment with either cefazolin or placebo. Risk factors for wound complications (age greater than 60 years, open wound, obesity, smoking, extremity edema, diabetes, arteriosclerotic cardiovascular disease) were recorded. The rate of complications was 36% in 97 patients (72%) with any risk factor present, compared with 14% in patients with no risk factors. Complications were seen in 30% of patients: in 14% after axillary lymph node dissection, and in 64% after inguinal lymph node dissection. The risk of complications was 23% in the group administered antibiotic treatment compared with 36% in that administered placebo treatment. This trend toward fewer complications was seen only after axillary lymph node dissection, when the rate of complications was 8% in the antibiotic-treated group compared with 20% in the placebo-treated group. After inguinal lymph node dissection, the rate of complications was 69% in the antibiotic-treated group compared with 62% in the placebo-treated group.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747049     DOI: 10.1001/archsurg.1991.01410350056009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

1.  Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.

Authors:  Sharon B Chang; Robert L Askew; Yan Xing; Storm Weaver; Jeffrey E Gershenwald; Jeffrey E Lee; Richard Royal; Anthony Lucci; Merrick I Ross; Janice N Cormier
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

2.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

3.  Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial.

Authors:  James W Jakub; Alicia M Terando; Amod Sarnaik; Charlotte E Ariyan; Mark B Faries; Sabino Zani; Heather B Neuman; Nabil Wasif; Jeffrey M Farma; Bruce J Averbook; Karl Y Bilimoria; Travis E Grotz; Jacob B Jake Allred; Vera J Suman; Mary Sue Brady; Douglas Tyler; Jeffrey D Wayne; Heidi Nelson
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

4.  Groin dissection in malignant melanoma.

Authors:  C P Karakousis; D L Driscoll; B Rose; D L Walsh
Journal:  Ann Surg Oncol       Date:  1994-07       Impact factor: 5.344

Review 5.  Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?

Authors:  E Mini; S Nobili; P Periti
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Wound infection after elective colorectal resection.

Authors:  Robert L Smith; Jamie K Bohl; Shannon T McElearney; Charles M Friel; Margaret M Barclay; Robert G Sawyer; Eugene F Foley
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 7.  Clinical decision-making in early breast cancer.

Authors:  C M Balch; S E Singletary; K I Bland
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

8.  Risk Factors for Wound Infections after Vascular Surgery: Kuwait Experience.

Authors:  Abdullah A AlFawaz; Ali H Safar; Ali Al-Mukhaizeem; Emad Kamal; Mohammed Alloush; Ebrahim Hanbal
Journal:  Med Princ Pract       Date:  2022-05-19       Impact factor: 2.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.